This trial is evaluating whether ticagrelor will improve 1 primary outcome and 1 secondary outcome in patients with Coronary Artery Disease. Measurement will happen over the course of up to 1 month.
This trial requires 60 total participants across 4 different treatment groups
This trial involves 4 different treatments. Ticagrelor is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 & 3 and have had some early promising results.
Coronary artery disease is associated with increased cardiovascular mortality. Patients with coronary artery disease may also suffer from disability and reduction of quality of life. The most frequent cause of death in patients with coronary artery disease belongs to recurrent coronary artery occlusion and complications of treatment, and these results depend greatly on the presence of concomitant peripheral vascular disease.
Atherosclerosis and heart artery disease can be due to a combination of the many genetic and environmental factors. There may also exist specific diseases such as the systemic amyloidosis and systemic lupus erythematosus, or diseases of heredity, or acquired factors such as smoking and diabetes. It is likely that it is caused by some factor of which there are many potential contributors.
Treatment options for coronary artery disease include a variety of different treatments. Typically, coronary artery disease is treated with a statin or drugs that lower cholesterol. Surgery is often recommended when people have severe problems with the blood vessels and other major organs. A number of coronary intervention techniques are available, including percutaneous coronary intervention (coronary angioplasty) and coronary artery bypass graft (possible graft placement) surgery. Many coronary artery diseases can be treated with medication(s) rather than surgery. Sometimes there is a combination of the two treatments in which case surgery is a part of the treatment plan.
Overall, approximately 32.1 million Americans are affected, and around 29.8% of these people have coronary artery disease. This makes it the most common cause of heart attacks and sudden cardiac death.
Coronary artery disease involves symptoms such as shortness of breath and chest pain. These may lead to the need for medications such as aspirin for low-risk individuals.\n
CAD is an important health condition that is associated with an increased risk of mortality in a population, especially on men of advanced age. However, the incidence of CAD in population is not sufficient to justify its treatment in population without comorbidities associated with more serious CAD.
Ticagrelor (as opposed to placebo or clopidogrel alone), like prasugrel, has proven effective in lowering the risk of thromboembolic events in patients with stable coronary artery disease (CAD) receiving percutaneous coronary intervention (PCI). The efficacy of ticagrelor appears to be similar to that of prasugrel to date. This promising benefit and excellent oral bioavailability makes ticagrelor a good option for this patient group.
Clinical trial recruitment depends, in part, on whether the study may change the standard of care. Those trials with limited expected effect are likely to attract few participants.
Although the prevalence of CAD in families of coronary cases exceeds that (50%) generally observed in case-ascertainment studies of family members of individuals with proven CAD, this does not imply that members of coronary families have an increased risk of CAD.
Only 2 have conducted ticagrelor clinical trials on patients admitted after a myocardial infarction, with the results presented in 2 publications. Only one of them has included an estimation of the sample size that needs to be recruited for the trial in order to detect a clinically relevant clinical effect. This may affect the number of treatments that can be evaluated in patients admitted for treatment after an myocardial infarction. The trial in the published study, which included 944 patients in 749 days, indicated an 18% reduction in the risk of 1-year death if patients were prescribed ticagrelor compared to patients who were prescribed clopidogrel.
A significant proportion of patients die prior to the occurrence of coronary artery disease; therefore, it is highly important to understand how this pathophysiology may affect health and modify disease risk.